Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up

Hanne Ø Larsen, Anne S Roug, Tom Just, Gordon D Brown, Peter Hokland

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.
Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalCytometry Part B: Clinical Cytometry
Volume82B
Issue number1
Early online date30 Aug 2011
DOIs
Publication statusPublished - Jan 2012

Fingerprint

C-Type Lectins
Stem Cell Research
Myeloid Cells
Acute Myeloid Leukemia
Flow Cytometry

Keywords

  • AML
  • hMICL
  • immunophenotyping
  • LAIP
  • MRD

Cite this

Expression of the hMICL in acute myeloid leukemia : a highly reliable disease marker at diagnosis and during follow-up. / Larsen, Hanne Ø; Roug, Anne S; Just, Tom; Brown, Gordon D; Hokland, Peter.

In: Cytometry Part B: Clinical Cytometry, Vol. 82B, No. 1, 01.2012, p. 3-8.

Research output: Contribution to journalArticle

Larsen, Hanne Ø ; Roug, Anne S ; Just, Tom ; Brown, Gordon D ; Hokland, Peter. / Expression of the hMICL in acute myeloid leukemia : a highly reliable disease marker at diagnosis and during follow-up. In: Cytometry Part B: Clinical Cytometry. 2012 ; Vol. 82B, No. 1. pp. 3-8.
@article{57a7d01c17a745f388668760974da5e5,
title = "Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up",
abstract = "Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.",
keywords = "AML, hMICL, immunophenotyping, LAIP, MRD",
author = "Larsen, {Hanne {\O}} and Roug, {Anne S} and Tom Just and Brown, {Gordon D} and Peter Hokland",
note = "Copyright {\circledC} 2011 International Clinical Cytometry Society.",
year = "2012",
month = "1",
doi = "10.1002/cyto.b.20614",
language = "English",
volume = "82B",
pages = "3--8",
journal = "Cytometry Part B: Clinical Cytometry",
issn = "1552-4949",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Expression of the hMICL in acute myeloid leukemia

T2 - a highly reliable disease marker at diagnosis and during follow-up

AU - Larsen, Hanne Ø

AU - Roug, Anne S

AU - Just, Tom

AU - Brown, Gordon D

AU - Hokland, Peter

N1 - Copyright © 2011 International Clinical Cytometry Society.

PY - 2012/1

Y1 - 2012/1

N2 - Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.

AB - Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.

KW - AML

KW - hMICL

KW - immunophenotyping

KW - LAIP

KW - MRD

U2 - 10.1002/cyto.b.20614

DO - 10.1002/cyto.b.20614

M3 - Article

C2 - 22173921

VL - 82B

SP - 3

EP - 8

JO - Cytometry Part B: Clinical Cytometry

JF - Cytometry Part B: Clinical Cytometry

SN - 1552-4949

IS - 1

ER -